JAK/TYK2

🔎Long-term malignancy risk remains an important consideration in RA treatment See the SELECT trial program 5-year malignancy risk data for a JAKi and TNFi in RA, including in high CV-risk patients: https://t.co/1PBrCKLRan Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/hxzGpxWW0s

Long-term Malignancy Risk, Including in Higher CV-Risk RA: a JAKi and TNFi | Rh…

📢 "We can't have a one-size-fits-all approach" – Dr. Saakshi Khattri Hear Dr. Khattri and Lindsay Tom, PA-C, explore the latest IL-23i and JAKi data and how it impacts their PsA treatment decisions. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/MOBlwXCFuu https://t.co/2pHRO1SQCS

Individualized PsA Treatment With an IL-23i or a JAKi | RheumNow

Is 60-40-20 broken? RA trial rule of thumb: roughly 60%-40%-20% for ACR20-50-70 girocitinib (JAK1/Tyk2) vs tofacitinib ACR20: 91% vs 75% ACR50: 73% vs 49% ACR70: 44% vs 25% there will be debate (all in China, tofa exposure) but what a meeting for H2H ABSTLB21 #ACR26 @RheumNow https://t.co/SmOCzqqxFg

https://x.com/drdavidliew/status/2120645121083633898/photo/1

Great @RheumNow Day 2 Daily Recap today talking about trends in SpA therapy, PsA and obesity, gout flares and CV risk, IL-17/23 in PMR/GCA, and as always a healthy dose of 'AI is coming/here'. All the good stuff from #ACR26 with @synovialjoints @AdelaCastro222 @ericdeinmd https://t.co/FSjr2Qn3JC

https://twitter.com/RheumNow/status/2119928161047650786

Just as tofacitinib goes generic, have we found a better option? TARA = giroctinib (JAK1/TYK2) vs. tofa in severe/refractory RA 39% with prior JAK exposure Week 4: ACR50 ~15% vs. 6% Week 24: ACR50 73% vs. ~50% Similar infx risk esp zoster, no MACE @RheumNow #ACR26 LB21 https://t.co/ZthsWSoedR

https://x.com/Dr_Brian_MD/status/2120530457288954091/photo/1

A#2929 JAKi vs TNFi in RA (TriNetX, N>32k): mortality HR 1.28 at 3yr, yet MACE null until 5yr (HR 1.06). Mortality ahead of MACE may reflect non-CV deaths? Channeling, confounding by indication and switchers may bias the comparison @rheumnow #ACR26

Another potential treatment for treating Sjogren's: LB22: Ph3b efficacy & safety of Dazodalibep (DZP), CD40/CD40L inhbition VS PBO: - Wk 48; both DZP regimens improved ESDAI (diff v PBO -1.8 & -1.4) - tx effect early as wk 4 - Pt reported dryness also improved @RheumNow #ACR26 https://t.co/qa4dyr3e40

https://x.com/AkhilSoodMD/status/2120516142250983495/photo/1

LB21: TARA - Phase 3, DB, active-controlled RCT Girocitinib (TLL-018) - highly selective JAK1/TYK2 dual inhibitor - vs JAKi in active RA refractory to bDMARDs ACR50 at 24wks: 73.0% versus 49.5% Potential option for D2T RA?! #ACR26 @RheumNow https://t.co/SGkZjP994P

https://x.com/JihaRheum/status/2120514883880181884/photo/1

TARA phase 3 (n=459): after bDMARD failure, week-24 ACR50 was 73.0% with girocitinib vs 49.5% with tofacitinib (p<0.0001). Serious infections: 3 vs 4. Findings support girocitinib as a promising treatment option for refractory RA. #LB21 #ACR26 @Rheumnow https://t.co/mjWW8GgRkm

https://x.com/DrMiniDey/status/2120514380815307168/photo/1

#girocitinib #JAK1/TYK2 v JAK1 #tofacitinib Good safety profile 1 thrombosis in #tofa Better outcomes 🛑 Tofa-IR allowed #ACR26 @RheumNow @ACRheum #LB21 https://t.co/6WJko54SRm

Zeng et al: TARA phase 3 in bDMARD-refractory RA: Week 24 ACR50 was 73.0% with girocitinib vs 49.5% with tofacitinib (p<0.0001). Impressive efficacy; longer-term safety remains critical. @rheumnow #ACR2026 Abstract#LB21

#JAK1/#TYK2i #girocitinib #H2H v #tofacitinib TARA RCT in #RA in #China post #bDMARD(s) #IR or #intolerance 🏆 Girocitinib 20mg bid n=450, low drop out #ACR50 wk24 and crossover of Tofa to Giro if not met Could be #JAKi exposed ?when to use ?other pop #LB21 #ACR26 @RheumNow https://t.co/dR2lsB6CGJ

https://x.com/Janetbirdope/status/2120512009275867592/photo/1

The late breaking abstracts are nearly here! And my most anticipated one: TARA Remember TLL-018, the Chinese JAK1/Tyk2 at #EULAR2023, smashing tofa in RA? https://t.co/bu5syrTaWQ We said: come back with your ph3 data They did. Same results ABSTLB21 #ACR26 #ACRBest @RheumNow https://t.co/9SmW54dPia

TARA trial: Ph3 H2H trial of Girocitinib (JAK1/TYK2i) vs Tofa in RA refractory to bDMARDs Giro achieved higher ACR50 response vs Tofa at wk24 (73 vs 49.5%) Also met secondary endpts Safety data: Infections more common. No VT/malignancy/MACE in Giro arm. @RheumNow #ACR26 LB21 https://t.co/HNVt7WdLc6

Article

Is It Still Inflammation?

Antoni Chan, MD, PhD Nov 11, 2026

A 34 year old female has axSpA. Her CRP is 3, her MRI is quiet, and her BASDAI is 7. She has tried two biologics and is asking about a third. Before we write that prescription, #ACR26 challenges us to ask a different question: is it still inflammation?

Zeng et al. TARA phase 3 RCT from China. 459 bDMARD-IR patients. Girocitinib (JAK1/TYK2i) superior to tofacitinib in RA. Better by week 4 and increasingly so over time. Numerically less serious adverse events 3.9% vs 6.6% also. @RheumNow #ACR26 Abstr#LB21 #ACRbest https://t.co/Yt406T3eyi

https://x.com/RichardPAConway/status/2120332431572312195/photo/1

NO small feat! A nanoparticle target of Myeloid inhibiting #JAK in #RA Some JAK #dendranib candidates have been found and are being studied Cool technology- need to follow this space #2028 #ACR26 @ACRheum @RheumNow https://t.co/X9E5LzyY0h

Knowledge doesn’t ‘LAG’ in #RA T cell inhibition #LAG-3 is inhibited by #IMP761 ⬇️T cell activation &proliferation in RA Strong rationale to consider new #MOA at higher doses Too early to know for sure re future efficacy but sound rational #LB09 #ACR26 @ACRheum @RheumNow https://t.co/AUjeWEIbaB

FASTLANE study: Significantly higher proportion of pts w/early active axSpA on Tofa 5mg BID/naproxen achieved ASDAS inactive dse vs. PBO/naproxen at wk 16 (26.4% vs. 7% p0.006) AEs occured in 50% of pts on TOFA vs. 33% on PBO. AEs: infections, GI @RheumNow #ACR26 Abs2314 #ACRbest https://t.co/QkxaNCDQsu

https://x.com/RHEUMarampa/status/2120199052688072917/photo/1

Standard vs. half-dose? RCT of Tofa 5mg OD (half-dose) was non-inferior to 11mg XR OD (std dose) in achieving ASAS20 response for axSpA Both tx arms met primary endpt of ASAS20 (p=0.159) Comparable outcomes of ASAS40, BASDAI50, ASDAS No new safety signals @RheumNow #ACR26 Abs2294 https://t.co/Vgo6xVkVm5

https://x.com/RHEUMarampa/status/2120189993196941456/photo/1

Does JAKi carry higher late MACE/VTE risk in PsA? TriNetX: no difference at 0-2 yrs, but at 2-5 yrs TNFi and IL-17i had HRs of 0.50 and 0.45 vs JAKi. Retrospective, small JAKi group, residual confounding possible. A#2304 @RheumNow #ACR26 https://t.co/wmpgay1ayF

https://x.com/JihaRheum/status/2120187728503386183/photo/1

He et al. Tofacitinib + 4 weeks GC vs standard GC in PMR. Equal efficacy. Far less steroids, and less diabetes and osteoporosis in tofa group. @RheumNow #ACR26 Abstr#2106 #ACRbest https://t.co/acH8RauYln

https://x.com/RichardPAConway/status/2120183198168559735/photo/1

Could blood proteins guide JAKi vs TNFi selection? A 7-protein model discriminated opposite 6-month remission outcomes in advanced-therapy-naive RA (AUC 0.75), but performed poorly after prior therapy (0.57). @Rheumnow #2829 #ACR26

Not just another ‘JAK’ Ph3 #RCT in active #RA 1 #bDMARD-IR 24w #Gyrocotinib #JAK1/Tyk2 vs Tofacitinib #JAK1 Gyro was superior #ACR50 73% vs 49.5% Replicating Ph2 results Other outcomes gyro>tofa Similar safety ?will results be replicated beyond China #LB21 #ACR26 @RheumNow https://t.co/ggN6X1kfED

https://t.co/WcQI9qnzUT

Dr. John Cush

Therapeutic Updates

A JAKi CHAT: Shared Decision-Making in RA

Sponsored by AbbVie Medical Affairs + Health Impact

Oct 01, 2025

Experts Dr. Jeffrey Curtis and Dr. Kevin Winthrop discuss best practices for shared decision-making, how to talk with patients about the risks of poorly controlled RA, and ways to use a new tool for visualizing the long-term safety of a JAKi.

Read Post

ACR 2026 Daily Podcasts - Day3b
Nov 11, 2026
ACR 2026 Daily Podcasts - Day2a
Nov 10, 2026
PsA Topic Podcast compilation
Jun 08, 2026

Topics

JAK/TYK2

Is It Still Inflammation?

Therapeutic Updates

A JAKi CHAT: Shared Decision-Making in RA

Poster Hall

Long-Term Safety of a JAKi in Clinical Trial and Real-World Settings Across >21,000 Patient-Years

Daily Download

Scope of Infections Associated with b/ts DMARDs

Podcasts

Topic Videos

Do you get our email newsletter?